NEW YORK (GenomeWeb News) – Illumina said today that it has entered into a three-year supply agreement with Natera, under which Natera will run its noninvasive prenatal test Panorama on Illumina's HiSeq 2500 and use the associated Illumina consumables.

"This deal enables a major expansion of Natera's laboratory capacity to support the fast-growing demand for our Panorama test," Natera CEO Matthew Rabinowitz said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.